There are various genetic testing methods available to determine whether early-stage hormone-positive breast cancer can benefit from chemotherapy. If the genetic report shows a low risk of recurrence, chemotherapy can be discontinued as recommended in the report. Even for individuals at intermediate or high risk, there are now new treatment options that can further reduce the risk of recurrence, thereby mitigating the increased risk of recurrence due to not receiving chemotherapy. These options include: LHRH injections and aromatase inhibitors (AIs), concurrent CDK4/6 inhibitors, etc.
Doctor Q&A
My elderly relative has invasive ductal carcinoma in the central region of the breast, nonspecific type, histological grade II. The cancer has spread to the fat and superficial dermis, with approximately 5% lymphocytes. It also has ductal carcinoma in situ (CTC), grade II. One of the 16 lymph nodes taken from the axilla has ITC. Pathological staging: pT2NO(ITC)Mx, ER-a positive 90%, PR positive 90%, HER2 1+, Ki-67 positive 20-30%, p53 positive 15%. She is very resistant to chemotherapy, so she opted for genetic testing, which showed a low-risk result. I would like to ask the doctor if it is possible to choose not to undergo chemotherapy?
- BRCA gene, HER2 gene, PIK3CA gene, breast cancer, Gene classification articles, Genetic testing, solid cancer, Information for newly diagnosed patients, Targeted therapy, Pathological diagnosis, Cancer treatment, Types of cancer, Cancer diagnosis, Hormone therapy